Skip to main content

Table 5 Lifetime costs (US$), effectiveness and ICERs of ART compared to No-ART

From: The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa – a primary data analysis

Treatment option Lifetime costs (95%CI) Outcomes ICER
   Life Years (95%CI) QALYs (95%CI) Life Years (95%CI) QALYs (95%CI)
Undiscounted
No-ART 2,966 (2,611–3,343) 2.9 (2.6–3.3) 2.1 (1.8–2.3)   
ART 13,191 (11,167–16,056) 12.9 (11.1–15.2) 10.8 (9.1–12.5) 1,023 (958–1,116) 1,166 (1,092–1,279)
Discounted
No-ART 2,743 (2,414–3,057) 2.7 (2.4–3.0) 1.9 (1.7–2.1)   
ART 9,435 (8,414–10,891) 9.5 (8.5–10.7) 8.0 (7.3–8.6) 984 (913–1,078) 1,102 (1,043–1,210)
  1. Lifetime costs and effectiveness are per patient in each group.
  2. † The ICER is calculated as incremental lifetime costs divided by incremental effectiveness.